Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials

Authors

Alexis Ogdie (ORCID: https://orcid.org/0000-0002-4639-0775)
Yu Deng (ORCID: https://orcid.org/0000-0003-4158-8966)
Philipp Sewerin (ORCID: https://orcid.org/0000-0001-8465-6207)
Andra Rodica Balanescu (ORCID: https://orcid.org/0000-0003-0688-9173)
Mitsumasa Kishimoto (ORCID: https://orcid.org/0000-0002-4007-1589)
Laure Gossec (ORCID: https://orcid.org/0000-0002-4528-310X)
Yunzhao Xing
Sheng Zhong (ORCID: https://orcid.org/0000-0002-2744-6243)
Linyu Shi
Ralph Lippe
Maria Antonietta D’Agostino
Yoshiyuki Sugimoto

Institutions

Università Cattolica del Sacro Cuore (IT)
Inserm (FR)
Carol Davila University of Medicine and Pharmacy (RO)
Kyorin University (JP)
Agostino Gemelli University Polyclinic (IT)
AbbVie (United States) (US)
Sorbonne Université (FR)
Rheumazentrum Ruhrgebiet (DE)
Assistance Publique – Hôpitaux de Paris (FR)
Pitié-Salpêtrière Hospital (FR)
ABB (Japan) (JP)
Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
AbbVie (Japan)
University of Pennsylvania (US)
Ruhr University Bochum (DE)

Publication Details

Journal: Arthritis Research & Therapy
Published: 2025-11-29
DOI: https://doi.org/10.1186/s13075-025-03670-0
Citations: 1
Primary Topic: Inflammatory Bowel Disease
Type: article
Field-Weighted Citation Impact: 1.82

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials

Alexis Ogdie, Yu Deng, Philipp Sewerin, Andra Rodica Balanescu et al.

Nov 29, 2025

1 citations

Arthritis Research & Therapy

Inflammatory Bowel Disease

1.82

article

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials

Alexis Ogdie, Yu Deng, Philipp Sewerin, Andra Rodica Balanescu, Mitsumasa Kishimoto, Laure Gossec, Yunzhao Xing, Sheng Zhong, Linyu Shi, Ralph Lippe, Maria Antonietta D’Agostino, Yoshiyuki Sugimoto

November 29, 2025article en

1 citations

Abstract

No abstract available for this paper.

Arthritis Research & TherapyVol. 28(1)

Università Cattolica del Sacro Cuore (IT), Inserm (FR), Carol Davila University of Medicine and Pharmacy (RO), Kyorin University (JP), Agostino Gemelli University Polyclinic (IT), AbbVie (United States) (US), Sorbonne Université (FR), Rheumazentrum Ruhrgebiet (DE), Assistance Publique – Hôpitaux de Paris (FR), Pitié-Salpêtrière Hospital (FR), ABB (Japan) (JP), Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR), AbbVie (Japan), University of Pennsylvania (US), Ruhr University Bochum (DE)

Openalex Percentile: Top 11%

Inflammatory Bowel Disease

1.82

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials — Alexis Ogdie, Yu Deng, et al. · Arthritis Research & Therapy (2025) | TGRS Research Map | TGRS